FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to therapy and immunology, and can be used for treating systemic lupus erythematosus (SLE). Three consecutive procedures are performed selective plasma adsorption of DNA using a "NucleoCor" sorption column with an interval of one day with underlying drug therapy. On the next day after the third procedure, 6 methylprednisolone 500 mg intravenously is administered intravenously.
EFFECT: method provides reducing the synthesis of autoantibodies by activated B-lymphocytes, normalizing the immune response, quickly achieving low activity of the disease, reducing the daily dose of prednisolone and reducing the risk of developing irreversible organ damage due to the rapid removal of pathological neutrophilic cell traps and free DNA from the bloodstream.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR TREATMENT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSIS | 1997 |
|
RU2157684C2 |
| METHOD FOR TREATMENT OF HUMAN SYSTEMIC LUPUS ERYTHEMATOSUS | 2015 |
|
RU2580301C1 |
| METHOD FOR DIAGNOSIS OF RENAL DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS | 2017 |
|
RU2677325C1 |
| METHOD FOR DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME IN PATIENTS WITH THROMBOSIS AND/OR OBSTETRIC PATHOLOGY | 2022 |
|
RU2804231C1 |
| METHODS AND COMPOSITIONS FOR TREATING LUPUS | 2010 |
|
RU2607022C2 |
| TREATING AUTOIMMUNE DISEASES WITH CD154 ANTIBODIES | 2015 |
|
RU2695443C2 |
| TACI-Fc FUSION PROTEIN AND ITS USE | 2019 |
|
RU2814988C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS AND SJOGREN DISEASE | 2023 |
|
RU2817079C1 |
| METHOD OF EARLY PREDICTION OF DEVELOPMENT OF NEPHRITIS IN INDUCED MODEL OF SYSTEMIC LUPUS ERYTHEMATOSUS AUTOIMMUNE DISEASE IN VIVO | 2018 |
|
RU2679320C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSTICS OF SYSTEMIC LUPUS ERYTHEMATOSUS AND ACUTE BACTERIAL INFLAMMATION | 0 |
|
SU1788468A1 |
